Thyrocare Technologies

Thyrocare delivered a strong Q4 FY26 with consolidated revenue of ₹224 croreCurrent reported value: ₹224 crore. No comparable prior figure is available in the source record. (+20Current reported value: 20. No comparable prior figure is available in the source record.% YoY) and PAT of ₹48.7 croreCurrent reported value: ₹48.7 crore. No comparable prior figure is available in the source record. (+128Current reported value: 128. No comparable prior figure is available in the source record.% YoY), driven by 21% growth in franchisee businessCurrent reported value: 21% growth in franchisee business. No comparable prior figure is available in the source record. and 23% in partnershipsCurrent reported value: 23% in partnerships. No comparable prior figure is available in the source record.. Test volumes surged 29% YoYCurrent reported value: 29% YoY. No comparable prior figure is available in the source record. due to aggressive biochemistry pricing, while gross margins expanded 113bps to 74.7% from vendor negotiations. Management guided for mid-to-high teens revenue growth in FY27, with 75% from volume and 25% from mix, and expects EBITDA margins to remain stable around 32-34% as operating leverage is reinvested into specialty expansion (genomics, allergy). Key risk: potential reagent price increases from dollar strength could pressure margins if not passed on.